Drug interaction study: capivasertib meets rosuvastatin
NCT ID NCT07088913
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how the cancer drug capivasertib changes the way the body processes rosuvastatin, a common cholesterol-lowering medicine. Twenty healthy adults took rosuvastatin alone and then with capivasertib to compare drug levels in their blood. The results will help guide safe dosing when these drugs are used together.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- capivasertib and rosuvastatin
- What this could lead to
- If successful, this study could help doctors understand how to safely combine capivasertib with rosuvastatin or similar drugs.
- What could go wrong
- This is a very early, small study in healthy volunteers, not patients. It only measures drug levels, not treatment effects or safety in real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Baltimore, Maryland, 21225, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates